A two-part, open label phase II trial: part one, dose escalation safety; part two, randomized/comparing CDP791 [alacizumab pegol] plus carboplatin/paclitaxel with carboplatin/paclitaxel alone in subjects with locally advanced or metastatic non-squamous non-small cell lung cancer

Trial Profile

A two-part, open label phase II trial: part one, dose escalation safety; part two, randomized/comparing CDP791 [alacizumab pegol] plus carboplatin/paclitaxel with carboplatin/paclitaxel alone in subjects with locally advanced or metastatic non-squamous non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Alacizumab pegol (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 20 Oct 2009 Actual end date (1 Jun 2009) added as reported by ClinicalTrials.gov.
    • 04 Aug 2009 Results have been reported at the 13th World Conference on Lung Cancer.
    • 30 Jul 2009 Status changed from active, no longer recruiting to completed, according to CLinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top